Form 4: Cidara Therapeutics Chief Medical Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Chief Medical Officer of Cidara Therapeutics, Taylor Sandison, sold shares to cover tax withholding obligations related to the vesting and settlement of RSUs.
Summary
- Taylor Sandison, Chief Medical Officer of Cidara Therapeutics, sold 924 shares of common stock on September 11, 2024, at a weighted average price of $11.6367.
- The sale was to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs) and was not a discretionary transaction.
- Following the transaction, Sandison beneficially owns 23,067 shares of Cidara Therapeutics.
- This number includes 200 shares acquired through the Employee Stock Purchase Plan on May 20, 2024, and reflects the 1-for-20 reverse stock split on April 24, 2024.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover taxes) by an executive, which is neither particularly positive nor negative.
Industry Context
Sales of shares to cover tax obligations are a routine part of executive compensation and are not necessarily indicative of the company's performance or future prospects.
Key Dates
| Date | Description |
|---|---|
| April 24, 2024 | 1-for-20 reverse stock split effected by the Issuer |
| May 20, 2024 | 200 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan |
| September 11, 2024 | Sale of 924 shares of common stock by Taylor Sandison |
| September 13, 2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.